NO20092099L - DMAE as sole agent for the treatment of mild cognitive impairment - Google Patents
DMAE as sole agent for the treatment of mild cognitive impairmentInfo
- Publication number
- NO20092099L NO20092099L NO20092099A NO20092099A NO20092099L NO 20092099 L NO20092099 L NO 20092099L NO 20092099 A NO20092099 A NO 20092099A NO 20092099 A NO20092099 A NO 20092099A NO 20092099 L NO20092099 L NO 20092099L
- Authority
- NO
- Norway
- Prior art keywords
- dmae
- treatment
- cognitive impairment
- mild cognitive
- sole agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0609548A FR2907679B1 (fr) | 2006-10-31 | 2006-10-31 | Utilisation de dmae pour le traitement de deficit cognitif leger |
PCT/EP2007/061737 WO2008053011A1 (fr) | 2006-10-31 | 2007-10-31 | Le dmae en tant qu'agent unique pour le traitement de deficit cognitif leger |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092099L true NO20092099L (no) | 2009-07-17 |
Family
ID=38050144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092099A NO20092099L (no) | 2006-10-31 | 2009-05-28 | DMAE as sole agent for the treatment of mild cognitive impairment |
Country Status (18)
Country | Link |
---|---|
US (1) | US8207218B2 (es) |
EP (1) | EP2083814B1 (es) |
JP (1) | JP2010508253A (es) |
KR (1) | KR20090082428A (es) |
CN (1) | CN101528220A (es) |
AR (1) | AR063764A1 (es) |
AU (1) | AU2007316137A1 (es) |
BR (1) | BRPI0718263A2 (es) |
CA (1) | CA2667983A1 (es) |
FR (1) | FR2907679B1 (es) |
IL (1) | IL198463A0 (es) |
MA (1) | MA30925B1 (es) |
MX (1) | MX2009004682A (es) |
NO (1) | NO20092099L (es) |
RU (1) | RU2009120137A (es) |
TN (1) | TN2009000159A1 (es) |
WO (1) | WO2008053011A1 (es) |
ZA (1) | ZA200903626B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150157046A1 (en) * | 2013-12-10 | 2015-06-11 | Lifewave, Inc. | Nutritional product composition for the mind |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003003981A2 (en) * | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
US20060211721A1 (en) * | 2005-03-21 | 2006-09-21 | Roberts Alan R | Nutraceutical formulation of a cognitive enhancement system |
-
2006
- 2006-10-31 FR FR0609548A patent/FR2907679B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-31 JP JP2009533884A patent/JP2010508253A/ja not_active Withdrawn
- 2007-10-31 AR ARP070104851A patent/AR063764A1/es not_active Application Discontinuation
- 2007-10-31 CN CNA2007800401804A patent/CN101528220A/zh active Pending
- 2007-10-31 MX MX2009004682A patent/MX2009004682A/es not_active Application Discontinuation
- 2007-10-31 RU RU2009120137/15A patent/RU2009120137A/ru not_active Application Discontinuation
- 2007-10-31 US US12/447,816 patent/US8207218B2/en not_active Expired - Fee Related
- 2007-10-31 BR BRPI0718263-5A patent/BRPI0718263A2/pt not_active IP Right Cessation
- 2007-10-31 AU AU2007316137A patent/AU2007316137A1/en not_active Abandoned
- 2007-10-31 EP EP07822084A patent/EP2083814B1/fr active Active
- 2007-10-31 KR KR1020097010586A patent/KR20090082428A/ko not_active Application Discontinuation
- 2007-10-31 WO PCT/EP2007/061737 patent/WO2008053011A1/fr active Application Filing
- 2007-10-31 CA CA002667983A patent/CA2667983A1/fr not_active Abandoned
-
2009
- 2009-04-24 TN TNP2009000159A patent/TN2009000159A1/fr unknown
- 2009-04-30 IL IL198463A patent/IL198463A0/en unknown
- 2009-05-26 ZA ZA200903626A patent/ZA200903626B/xx unknown
- 2009-05-27 MA MA31926A patent/MA30925B1/fr unknown
- 2009-05-28 NO NO20092099A patent/NO20092099L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2009004682A (es) | 2009-09-28 |
US20090298908A1 (en) | 2009-12-03 |
EP2083814A1 (fr) | 2009-08-05 |
FR2907679B1 (fr) | 2009-10-30 |
KR20090082428A (ko) | 2009-07-30 |
FR2907679A1 (fr) | 2008-05-02 |
ZA200903626B (en) | 2010-07-28 |
IL198463A0 (en) | 2010-02-17 |
EP2083814B1 (fr) | 2013-03-20 |
CN101528220A (zh) | 2009-09-09 |
JP2010508253A (ja) | 2010-03-18 |
BRPI0718263A2 (pt) | 2014-01-07 |
US8207218B2 (en) | 2012-06-26 |
MA30925B1 (fr) | 2009-11-02 |
TN2009000159A1 (fr) | 2010-10-18 |
RU2009120137A (ru) | 2010-12-10 |
AU2007316137A1 (en) | 2008-05-08 |
WO2008053011A1 (fr) | 2008-05-08 |
CA2667983A1 (fr) | 2008-05-08 |
AR063764A1 (es) | 2009-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507198A (pt) | derivados de bisariluréia | |
DK1807072T3 (da) | Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1 | |
NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer | |
SG171649A1 (en) | Dpp iv inhibitor formulations | |
BRPI0908421C1 (pt) | solução estável de um composto farmacêutico | |
MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
NO20065880L (no) | 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor | |
DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
PT2222669E (pt) | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) | |
WO2007144327A3 (en) | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands | |
UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
NO20092535L (no) | Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol | |
MX2012000488A (es) | Terapia de combinacion para el tratamiento de la diabetes. | |
CL2008001465A1 (es) | Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer. | |
EA201070477A1 (ru) | Транс-кломифен для лечения метаболического синдрома | |
WO2008063933A3 (en) | Pak modulators | |
NO20083905L (no) | Nye pyron-indol derivater og fremgangsmate for deres fremstilling | |
NO20075920L (no) | Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria | |
EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
NI200900052A (es) | Heterocíclicos derivados de los inhibidores de metaloproteasa | |
NO20080936L (no) | Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |